Wednesday, July 1, 2026

HomeHealth NewsFDA approves subcutaneous opdivo qvantig for most solid tumor indications

FDA approves subcutaneous opdivo qvantig for most solid tumor indications

- Advertisement -

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications.

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed